As cognitive decline generally does not appear prior to tau burden measurable with PET, this result suggests that LATE, or another non‐AD pathology, is likely to contribute to these memory changes prior to manifest clinical AD in at least a subset of these patients. The gene discussed is MAPT; the disease is Mental deterioration.